- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| VALION BIO Aktie jetzt für 0€ handeln | |||||
| Fr | Valion Bio, Inc. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| Do | Valion Bio, Inc.: Ukraine's Ministry Of Health Advances Entolimod Review Into Technical Assessment Phase | 320 | ACCESS Newswire | Potential Fourth-Quarter 2026 Decision Could Mark Entolimod's First National Registration and Open a Pathway to Strategic Stockpiling and Government ProcurementFormal review accepted July 22 • Ministry... ► Artikel lesen | |
| Mi | Valion Bio, Inc.: Valion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI Injury | 762 | ACCESS Newswire | AFRRI/NIAID Program to Advance Safety and Therapeutic Studies in Rapid Sequence; Top-Line Therapeutic Data Expected in Early FallStudy drug delivered • IACUC approval secured • Safety study planned... ► Artikel lesen | |
| 20.07. | Sheba Medical Center to evaluate Valion Bio's Entolimod in trial | 4 | Investing.com | ||
| 20.07. | Sheba Medical Center prüft Entolimod von Valion Bio in klinischer Studie | 1 | Investing.com Deutsch | ||
| 17.07. | Valion Bio, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 14.07. | Valion Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 18.06. | Valion Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 05.06. | Valion Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 03.06. | Valion Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.05. | Valion Bio outlines end-2026 Entolimod GMP validation target as NIAID funds GI-ARS BLA-enabling work | 2 | Seeking Alpha | ||
| 14.05. | Valion Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.05. | Valion Bio subsidiary secures exclusive NMR platform license | 1 | Investing.com | ||
| 14.05. | Valion Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | Valion Bio, Inc.: Valion Bio Reports First Quarter 2026 Financial Results | 284 | PR Newswire | First Reporting Quarter as Valion Bio Marked by Continued Advancement of the Entolimod Platform, Broader Government Engagement, and Continued Integration of Velocity... ► Artikel lesen | |
| 05.05. | Valion Bio receives protocol for radiation syndrome drug study | 3 | Investing.com | ||
| 05.05. | Tivic Health Systems, Inc.: Valion Bio Receives First FDA-precedent Study Protocol From Niaid For Entolimod; Federal Agency To Fully Fund Bla-enabling In Vivo Program And Co-navigate FDA Submission | 262 | PR Newswire | Initial Study to Evaluate Entolimod for Gastrointestinal Tissue Preservation in Partial-Body Acute Radiation Syndrome - an Indication for Which No Currently Approved... ► Artikel lesen | |
| 04.05. | Valion Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 24.04. | Tivic Health Systems Rebrands to Valion Bio | 2 | Contract Pharma | ||
| 24.04. | Tivic Health Systems (TIVC) Stock Surges Over 24% After Hours: Here's What Is Happening | 2 | Benzinga.com |
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HEARTFLOW | 42,110 | +0,07 % | Heartflow, Inc.: Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 Guidance | SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing coronary artery disease (CAD), today reported financial results... ► Artikel lesen | |
| FRESENIUS | 47,080 | -1,22 % | EQS-News: Fresenius SE & Co. KGaA: Fitch Ratings hebt Ausblick für Fresenius SE von stabil auf positiv an | EQS-News: Fresenius SE & Co. KGaA
/ Schlagwort(e): Rating
Fitch Ratings hebt Ausblick für Fresenius SE von stabil auf positiv an
10.08.2026 / 14:30 CET/CEST
Für den... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 39,310 | +0,69 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 41,040 | +0,12 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| AVEANNA HEALTHCARE | 12,310 | -0,08 % | Biotech Stocks At 52-Week Highs - PARK +10%, AVAH +24%, CADL +10% On Q2 Reports, LH, COAG | LONDON (dpa-AFX) - The following biotech stocks reached 52-week highs on August 13, 2026, driven by key catalysts such as positive quarterly reports and the issuance of increased guidance figures.Park... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 32,280 | +6,04 % | Märkte am Morgen: Boeing, Palo Alto, SAP, Infineon, Aixtron, TAG Immobilien, Südzucker, Carl Zeiss | Der DAX dürfte seinen Rekordkurs trotz verhaltener Wall-Street-Vorgaben verteidigen. Im Fokus stehen der wieder steigende Ölpreis, die niedrigen strategischen US-Reserven und die anhaltende Unsicherheit... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 61,73 | 0,00 % | BrightSpring Health Services, Inc. Reports Second Quarter 2026 Financial Results and Increases Full Year 2026 Guidance | LOUISVILLE, Ky., July 31, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services... ► Artikel lesen | |
| PROGYNY | 26,280 | 0,00 % | Progyny, Inc. Announces Second Quarter 2026 Results | Reports Record Quarterly Revenue, Gross Profit and Adjusted EBITDARobust Selling Season Activity Continues to Reflect Strong Demand for Women's Health, Family Building SolutionsValue Returned to Shareholders... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 13,950 | -0,07 % | Alignment Healthcare Reports Second Quarter 2026 Results, Surpassing High End of Guidance Across All Key Metrics | Generates $1.3 billion in total revenue, representing 31.6% growth year-over-year Grows Medicare Advantage membership 31.5% year-over-year to approximately 294,100 membersRaises the midpoint of all... ► Artikel lesen | |
| LIFESTANCE HEALTH GROUP | 12,415 | 0,00 % | LifeStance Health gains as Hedgeye adds as new long idea | ||
| SANARA MEDTECH | 34,140 | -0,03 % | Sanara MedTech Inc. Reports Second Quarter 2026 Financial Results (Unaudited) | FORT WORTH, TX, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," "Sanara MedTech," the "Company," "we," "our" or "us") (Nasdaq: SMTI), a medical technology company focused on developing... ► Artikel lesen | |
| BILLIONTOONE | 93,34 | +0,01 % | Diagnostiksektor: BTIG kürt BillionToOne zum Top-Pick | ||
| BETA BIONICS | 17,570 | 0,00 % | Beta Bionics, Inc.: Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance | IRVINE, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| GERRESHEIMER | 27,160 | +0,97 % | EQS-PVR: Gerresheimer AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Gerresheimer AG
Gerresheimer AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of... ► Artikel lesen | |
| GENEDX | 78,16 | +0,10 % | GeneDx launches online exome testing for pediatric patients |
Das Unternehmen VALION BIO INC kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,000 (+0,21 %) liegt der Kurs bei 0,191 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VALION BIO INC finden Sie auf Wallstreet Online.